ArticleBrain research2013
Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease.
Article in Brain research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Longitudinal Changes in the Digitized Archimedes Spiral Drawing Test Following iTBS of the Left DLPFC in Parkinson's Disease: An Exploratory Feasibility Study.Journal of clinical medicine · 2026Article
- Prefrontal parvalbumin neurons as a target for enhancing cognition in non-pathological and 22q11.2 microdeletion syndrome mice.Molecular psychiatry · 2026Article
- Early retinal synaptic dysfunction and proteomic remodeling precede neurodegeneration in a Parkinson's disease model.NPJ Parkinson's disease · 2026Article
- Remodeling of Perineuronal Nets in the Striato-Cortical Axis in L-DOPA-Induced Dyskinesia Rat Model.International journal of molecular sciences · 2025Article
- Human α-synuclein aggregation activates ferroptosis leading to parvalbumin interneuron degeneration and motor learning impairment.Communications biology · 2024Article
- Dysfunction of motor cortices in Parkinson's disease.Cerebral cortex (New York, N.Y. : 1991) · 2024Review
- Article
- Retinoic Acid Prevents the Neuronal Damage Through the Regulation of Parvalbumin in an Ischemic Stroke Model.Neurochemical research · 2023Article
- Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Quercetin attenuates the reduction of parvalbumin in middle cerebral artery occlusion animal model.Laboratory animal research · 2021Article
- Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators.Journal of personalized medicine · 2020Article
- The human motor cortex microcircuit: insights for neurodegenerative disease.Nature reviews. Neuroscience · 2020Review
- Reward-representing D1-type neurons in the medial shell of the accumbens nucleus regulate palatable food intake.International journal of obesity (2005) · 2019Article
- Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease.Frontiers in pharmacology · 2019Review
- Predictive encoding of motor behavior in the supplementary motor area is disrupted in parkinsonism.Journal of neurophysiology · 2018Article
- Progression Rate Associated Peripheral Blood Biomarkers of Parkinson's Disease.Journal of molecular neuroscience : MN · 2018Article
- The role of CaDisease models & mechanisms · 2017Review
- Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Journal of neuroscience research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
It has recently been shown that expression of the rate-limiting GABA-synthesizing enzyme glutamic acid decarboxylase (GAD) is decreased in Brodmann area 9 (BA9) of the dorsolateral prefrontal cortex (DLPFC) in Parkinson's disease (PD) compared to control brains (Lanoue, A.C., Dumitriu, A., Myers, R.H., Soghomonian, JJ., 2010. Exp. Neurol. 206 (1), 207-217). A subpopulation of cortical GABAergic interneurons expresses the calcium-binding protein parvalbumin and plays a critical role in the control of pyramidal neuron excitability and the generation of cortical gamma frequency oscillations. In view of its key role in the physiology of the cerebral cortex, we sought to determine whether the expression of parvalbumin and the number of parvalbumin-expressing neurons are altered in BA9 of PD brains. First, isotopic in situ hybridization histochemistry was used to examine mRNA expression of parvalbumin on post-mortem brain sections. Second, immunohistochemistry and design-based stereology were used to determine the density of parvalbumin-positive interneurons in BA9. Quantification of mRNA labeling at the single cell level showed a significant decrease in parvalbumin expression in PD cases. In contrast, neuronal density of parvalbumin-positive neurons was not significantly different between PD and controls. Results confirm that the GABAergic system is altered in the DLPFC in PD and identify the contribution of parvalbumin-expressing neurons in these alterations. We speculate that these effects could contribute to altered cortical excitability and oscillatory activity previously documented in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.